CASI Pharmaceuticals (NASDAQ:CASI) Issues Earnings Results

CASI Pharmaceuticals (NASDAQ:CASIGet Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05), reports. The company had revenue of $6.03 million during the quarter, compared to analysts’ expectations of $9.40 million. CASI Pharmaceuticals had a negative return on equity of 72.13% and a negative net margin of 79.30%.

CASI Pharmaceuticals Trading Up 20.3 %

NASDAQ:CASI opened at $3.61 on Friday. CASI Pharmaceuticals has a 52 week low of $1.85 and a 52 week high of $8.48. The firm has a 50-day moving average price of $5.19 and a two-hundred day moving average price of $4.86.

Analyst Upgrades and Downgrades

Separately, assumed coverage on CASI Pharmaceuticals in a report on Thursday. They set a “hold” rating for the company.

Get Our Latest Research Report on CASI Pharmaceuticals

Hedge Funds Weigh In On CASI Pharmaceuticals

Several institutional investors have recently modified their holdings of CASI. Susquehanna International Group LLP boosted its position in CASI Pharmaceuticals by 70.6% in the fourth quarter. Susquehanna International Group LLP now owns 57,395 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 23,758 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of CASI Pharmaceuticals during the 3rd quarter worth $27,000. Virtu Financial LLC boosted its holdings in shares of CASI Pharmaceuticals by 39.6% in the 1st quarter. Virtu Financial LLC now owns 112,777 shares of the biotechnology company’s stock worth $91,000 after buying an additional 31,971 shares during the last quarter. Finally, Citigroup Inc. bought a new position in CASI Pharmaceuticals during the first quarter valued at about $59,000. 22.23% of the stock is owned by institutional investors.

CASI Pharmaceuticals Company Profile

(Get Free Report)

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.

See Also

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with's FREE daily email newsletter.